Blinatumomab Becomes Standard Addition to Consolidation Chemo in B-ALL, Irrespective of MRD Status
Daniel DeAngelo, MD, PhD, discusses the expanded role of blinatumomab in B-cell precursor acute lymphoblastic leukemia management
Related Articles
Minimally Invasive Surgery Deemed Safe, Effective for “Oldest Old” Patients With Endometrial Cancer
Researchers found that robotic-assisted surgery, laparoscopic surgery, and vaginal surgery produced similar outcomes in patients who were 85 years of age or older.
Novel anti-HER2 ADCs vs dual anti-HER2 antibody for HER2-positive metastatic breast cancer failed to tyrosine kinase inhibitor
The aim of this study is to compare the efficacy and safety of a novel anti-HER2 antibody drug conjugate combined with HP (pertuzumab and trastuzumab)…
Galinpepimut-S Completes Phase 3 REGAL Interim Analysis in AML
Interim phase 3 results revealed a median survival of at least 13.5 months with galinpepimut-S vs 6 months with standard of care in acute myeloid…
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Venetoclax Plus BTK Inhibitor–Based Combinations Represent Promising Avenue in CLL/SLL
Supriya Gupta, MD, details pros/cons with different BTK inhibitors and promising combination therapies in CLL, as well as how liso-cel is affecting care.
Texan judge blocks US FDA changes on cigarette packaging
The US Food and Drug Administration (FDA) is pushing to reduce the levels of nicotine in cigarettes and other combusted tobacco products to make them…
India is boosting vaccination efforts to eradicate cervical cancer
A new initiative, led by the Indian Medical Association (IMA) and the Federation of Obstetric and Gynaecological Societies of India (FOGSI), seeks to eliminate cervical…
Membership – Society of Surgical Oncology
Join over 3,000 surgical oncologists worldwide. The Society of Surgical Oncology (SSO) is dedicated to improving multidisciplinary patient care by advancing the science, education, and…
Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma
Subcutaneous isatuximab plus Pd led to a noninferior ORR and observed concentration before dosing at steady state vs IV isatuximab plus Pd in RRMM.